Straits Times Index
3,176.51 -11.15 (-0.35%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,224.14 -161.73 (-0.99%) FTSE 100
7,833.84 -43.21 (-0.55%) Bitcoin USD
65,012.58 +2,845.95 (+4.58%) CMC Crypto 200
1,342.95 +30.33 (+2.37%)
Can-Fite BioPharma Ltd. (CANF)
Pre-market:
| Previous close | 1.9600 |
| Open | 2.0000 |
| Bid | 1.8100 x 1400 |
| Ask | 2.4600 x 800 |
| Day's range | 1.9600 - 2.0700 |
| 52-week range | 1.6800 - 3.3300 |
| Volume | |
| Avg. volume | 20,950 |
| Market cap | 9.877M |
| Beta (5Y monthly) | 0.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.0000 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 12.00 |
Business WireCan-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
PETACH TIKVA, Israel, April 15, 2024--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that Biomedicines published an article titled "Namodenoson at the Crossroad of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Hepatocellular Carcinoma (HCC)". Biomedicines is a highly reputable journal that publishes articles on clinical an
Business WireCan-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
RAMAT GAN, Israel, April 03, 2024--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), for the Company’s on
Business WireCan-Fite Reports 2023 Financial Results and Clinical Update
RAMAT GAN, Israel, March 28, 2024--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and clinical updates for the twelve months ended December 31, 2023.
